Real-time trade and investing ideas on Akebia Therapeutics AKBA from the largest community of traders and investors. Per consentire a Verizon Media e ai suoi partner di trattare i tuoi dati, seleziona 'Accetto' oppure seleziona 'Gestisci impostazioni' per ulteriori informazioni e per gestire le tue preferenze in merito, tra cui negare ai partner di Verizon Media l'autorizzazione a trattare i tuoi dati personali per i loro legittimi interessi. Zumwalt was most recently Group Vice President, Government Affairs at DaVita Inc., one of … AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. Akebia Therapeutics focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Just click the link Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. Find market predictions, AKBA financials and market news. On PennyStocks.com you will find a comprehensive list of Penny Stocks & discover the best Penny Stocks to buy, top penny stock news and micro-cap stock articles. The Motley Fool - … Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Login Ratings...FREE! Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 2:50 p.m. EST. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Dow Jones, a News Corp company. UAMY. Copyright © 2021. Stocks with similar financial metrics, market capitalization, and price volatility to Akebia Therapeutics Inc are. AKBA Akebia Therapeutics Inc Statement of Changes in Beneficial Ownership (4) FORM 4 [ ] Check this box if no longer subject to Section 16. In the news. 4.3700 +0.06 (1.39%) After hours: … However, with a daily trading volume of 4.79 million and changing 2.68% at the moment leaves the stock -57.77% off its SMA200. All 'A' Rated Buy Stocks, • How to Ride the 2021 Stock Market Bubble, • Mimecast Secures Stock of the Week Honors, • Stay Away From These 3 Overvalued EV Stocks, • Forget Palo Alto Networks, Buy These 3 Cyber-security Stocks Instead, Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights, 10 Underperforming Stocks Targeted By Short Sellers, Return On Capital Employed Overview: Akebia Therapeutics, Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference, Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference, Akebia Therapeutics Inc (AKBA) Stock Price | Nasdaq, Akebia Therapeutics Inc (AKBA) Stock Quote, History and News - Yahoo Finance, Akebia Therapeutics Inc (AKBA) Stock Price and Basic Information | MarketWatch. During Q3, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $59.99 million. In Q3, Akebia Therapeutics posted an ROCE of -0.18%. Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 ... SNPR, VLTA. The company was founded in 2007 and is based in Cambridge, Massachusetts. In this article we will list 10 underperforming stocks targeted by short sellers. Airbus lost $1.3 billion amid pandemic; expects better 2021. Latest AKBA News From Around the Web. 3 Stocks to Buy That Hedge Funds Love. The current RSI for AKBA stock in for the last two-week period is set at 56.01, with the RSI for the last a single of trading hit 51.99, and the three-weeks RSI is set at 57.20 for Akebia Therapeutics Inc. [AKBA]. Form 4 or Form 5 obligations may continue. Stock Market News; AKBA; Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights; Trending News. America’s Car-Mart (NASDAQ:CRMT) Sets New High As Business Accelerates. Q2 2020. Akebia Therapeutics, Inc. (AKBA) NasdaqGM - NasdaqGM Real Time Price. Annual. A rank of 50 means that 50% of stocks appear more favorable to our system. Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AKBA comes in at -47.46% -- higher than that of only 4.95% of stocks in our set. About Akebia TherapeuticsAkebia Therapeutics ( AKBA ), Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Ticker Update. above. Coty Stock Providing Pullback Opportunities . Penny Stocks (PennyStocks.com) is the top online destination for all things Micro-Cap Stocks. Log In. Akebia's shares jump on late-stage clinical trial results for kidney disease drug Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease. Per saperne di più su come utilizziamo i tuoi dati, consulta la nostra Informativa sulla privacy e la nostra Informativa sui cookie. Announces $23 Million Registered Direct Offering of Common Stock Priced ... TNXP. Quarterly. DBT News. View breaking news headlines for AKBA stock from trusted media outlets at MarketBeat. TradingView . Find market predictions, AKBA financials and market news. AKBA registered -57.06% … See Ticker Trading Ideas Educational Ideas Scripts People. S&P 500 3,913.97. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. View real-time stock prices and stock quotes for a full financial overview. AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. The volatility of Akebia Therapeutics Inc's share price is greater than that of 95.73% US stocks with at least 200 days of trading history. Find the latest news headlines from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Join. Friday, February 12, 2021. type here... Search. Just enter your email address below. Ocugen Inc. Over the past 26 days, the trend for AKBA's stories per day has been choppy and unclear. Q4 2019. Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. STOCKS FALL AFTER JOBLESS CLAIMS DATA DISAPPOINTS. AKBA News Highlights. Home. A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Currency in USD. Akebia … Akebia Therapeutics Inc. [AKBA] moved up 12.20: Why It’s Important. Sign Up to See What Is ROCE? What's going on at Akebia Therapeutics (NASDAQ:AKBA)? How Does Akebia Therapeutics Inc (AKBA) Stock Rank on Wall Street? Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Changes in earnings and sales indicate shifts in Akebia Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. ARDS are the most mentioned tickers in articles about AKBA. Equity Analysis - Advertisement - TAG. Misty Lee-February 9, 2021 0. 16 hours ago. InvestorsObserver. Yahoo fa parte del gruppo Verizon Media. We have 9 different ratings for every stock to help you The options have an exercise price of $3.24 per share, which is equal to the closing price of Akebia's common stock on the grant date. DOW 0.00%. Akebia Therapeutics Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time AKBA stock price. S&P 500 0.00%. What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 50, which is below average. OCGN. Sign Up. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2020 ended December 31, 2020, on Thursday, February 25, 2021, before the opening of the financial markets. STOCK MARKET NEWS LIVE UPDATES. TradingView. Stock Alert: Akebia Therapeutics Up 25% As Drug Trial Achieves Positive Results RTTNews 288d Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates Rooms Shows Rankings Earnings Calendar Shop. Noi e i nostri partner memorizzeremo e/o accederemo ai dati sul tuo dispositivo attraverso l'uso di cookie e tecnologie simili, per mostrare annunci e contenuti personalizzati, per la misurazione di annunci e contenuti, per l'analisi dei segmenti di pubblico e per lo sviluppo dei prodotti. It has oscillated between 1 and 2. 4.3100-0.2950 (-6.41%) At close: 4:00PM EST. Click to skip ahead and see the Top 5 Underperforming Stocks Targeted By Short Sellers. Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. To see all exchange delays and terms of use, please see disclaimer. Finance. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. AKBA stock. Short-sellers have invited the wrath of millions on the internet, causing one of the biggest short squeezes in the history of financial markets. appreciate its future potential. With a year-over-year growth in debt of 247.44%, Akebia Therapeutics Inc's debt growth rate surpasses 94.15% of about US stocks. AKBA stock news . AKBA Stock Summary. Stability and Growth of Payments Stable Dividend : Insufficient data to determine if AKBA's dividends per share have been stable in the past. Stock Titan Trading tools for traders and investors. Q3 2020. With a year-over-year growth in debt of 247.44%, Akebia Therapeutics Inc's debt growth rate surpasses 93.97% of about US stocks. Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investing decisions. 2020 is expected to be a … View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a late-stage study of … Below are the latest news stories about Akebia Therapeutics Inc that investors may wish to consider to help them evaluate AKBA as an investment opportunity. The Relative Strength Index (RSI, 14) currently prints 56.01, while 7-day volatility ratio is 8.17% and 9.92% in the 30-day chart. However, earnings decreased 66.58%, resulting in a loss of $58.09 million. Real-time trade and investing ideas on Akebia Therapeutics AKBA from the largest community of traders and investors. NASDAQ 0.00%. AKBA’s announcement was unexpected and the sudden plunge of its stock price reflects that. Financial performance. Cancel. In Q2, Akebia Therapeutics brought in $90.14 million in sales but lost $173.82 million in earnings. The present Moving Average for the last 50 days of trading for this stock 3.42, while it was recorded at 4.63 for the last single week of trading, and 6.74 for the last 200 days. 09:23:53 PM. US Equities. QQQ 332.47. It is a good measure of a company's recent performance, but sever... Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 – 14, 2021. Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha. Informazioni su dispositivo e connessione Internet, incluso l'indirizzo IP, Attività di navigazione e di ricerca durante l'utilizzo dei siti web e delle app di Verizon Media. For AKBA, its 30 day story count is now at 5. Akebia Therapeutics Inc (AKBA) Stock Price | NasdaqAkebia Therapeutics Inc (AKBA) Stock Quote, History and News - Yahoo FinanceAkebia Therapeutics Inc (AKBA) Stock Price and Basic Information | MarketWatch. Add to watchlist. In terms of volatility of its share price, AKBA is more volatile than 95.53% of stocks we're observing. Covid19; FDA approvals; Earnings; Merger & Acquisitions; Home; Stock Market News; AKBA; Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors ; Trending News. Trending now. GameStop shares briefly reverse losses, trade 3% higher after Keith Gill touts stock during congressional testimony . Q1 2020. United States Antimony Corporation Announces Receipt of Warning Letter from NYSE ... NVAX. DOW 31,493.34. High Dividend: Unable to evaluate AKBA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. Year to date, GameStop […]. S&P 500 3,913.97 (-0.44%) DOW 31,493.34 (-0.38%) QQQ 332.51 (-0.43%) AAPL 129.48 (-1.04%) MSFT 243.64 (-0.23%) FB 269.15 (-1.62%) GOOGL 2,106.00 (-0.60%) AMZN … You can unlock it all now. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. View live AKEBIA THERAPEUTICS INC chart to track its stock's price action. EN. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. View breaking news headlines for AKBA stock from trusted media outlets at MarketBeat. The technical evaluation for the stock shows the PEG ratio is 0, with AKBA’s current price about 7.86% and 26.77% off the 20-day and 50-day simple moving averages respectively. Puoi modificare le tue preferenze in qualsiasi momento in Le tue impostazioni per la privacy. Market - Local. Stock Stories. CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of LeAnne M. Zumwalt to its Board of Directors, effective February 16, 2021.Ms. Currently trading at $3.07, the stock is 3.66% and 8.47% above its SMA20 and SMA50 respectively.